DE69810612D1 - Pharmazeutische Zusammensetzungen mit Plasmaproteinen - Google Patents

Pharmazeutische Zusammensetzungen mit Plasmaproteinen

Info

Publication number
DE69810612D1
DE69810612D1 DE69810612T DE69810612T DE69810612D1 DE 69810612 D1 DE69810612 D1 DE 69810612D1 DE 69810612 T DE69810612 T DE 69810612T DE 69810612 T DE69810612 T DE 69810612T DE 69810612 D1 DE69810612 D1 DE 69810612D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
plasma proteins
proteins
plasma
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69810612T
Other languages
English (en)
Other versions
DE69810612T2 (de
Inventor
Lajos Hegedues
Krisztina Krempels
Krisztina Paal
Gabor Petho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Works PLC
Original Assignee
Human RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human RT filed Critical Human RT
Publication of DE69810612D1 publication Critical patent/DE69810612D1/de
Application granted granted Critical
Publication of DE69810612T2 publication Critical patent/DE69810612T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
DE69810612T 1997-09-18 1998-09-17 Pharmazeutische Zusammensetzungen mit Plasmaproteinen Expired - Lifetime DE69810612T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701554A HUP9701554D0 (en) 1997-09-18 1997-09-18 Pharmaceutical composition containing plazma proteins
PCT/HU1998/000086 WO1999013914A1 (en) 1997-09-18 1998-09-17 Pharmaceutical compositions containing plasma protein

Publications (2)

Publication Number Publication Date
DE69810612D1 true DE69810612D1 (de) 2003-02-13
DE69810612T2 DE69810612T2 (de) 2003-10-02

Family

ID=90014222

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69810612T Expired - Lifetime DE69810612T2 (de) 1997-09-18 1998-09-17 Pharmazeutische Zusammensetzungen mit Plasmaproteinen

Country Status (33)

Country Link
US (5) US6743826B1 (de)
EP (1) EP0981375B1 (de)
JP (1) JP2001508806A (de)
KR (1) KR100587962B1 (de)
CN (1) CN1189216C (de)
AR (1) AR017120A1 (de)
AT (1) ATE230611T1 (de)
AU (1) AU734695B2 (de)
BG (1) BG64749B1 (de)
BR (1) BR9812469A (de)
CA (1) CA2269923C (de)
CZ (1) CZ301326B6 (de)
DE (1) DE69810612T2 (de)
DK (1) DK0981375T3 (de)
EA (1) EA004700B1 (de)
ES (1) ES2187062T3 (de)
HR (1) HRP980499A2 (de)
HU (1) HUP9701554D0 (de)
IL (1) IL135055A (de)
LT (1) LT4736B (de)
LV (1) LV12493B (de)
NO (1) NO325294B1 (de)
NZ (1) NZ503302A (de)
PL (1) PL193067B1 (de)
PT (1) PT981375E (de)
RO (1) RO118695B1 (de)
RS (1) RS50102B (de)
SI (1) SI20189B (de)
SK (1) SK284683B6 (de)
TR (1) TR200001545T2 (de)
TW (1) TWI222365B (de)
WO (1) WO1999013914A1 (de)
ZA (1) ZA988585B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2000047187A1 (en) * 1999-02-11 2000-08-17 Kinetana Inc. Serum albumin-based parenteral formulations of polyene macrolides
MXPA02002439A (es) 1999-09-16 2002-07-30 Novo Nordisk As Composicion para fertilizacion in vitro.
AU2001253336A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
BR0110150A (pt) * 2000-04-10 2004-04-27 Teva Pharma Método e composição para o tratamento de câncer por meio da administração de agentes quimioterápicos indutores da apoptose
US20020192280A1 (en) * 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
EA200500210A1 (ru) 2002-07-16 2005-06-30 Медексис С. А. Конъюгаты стероидов, их получение и их применение
GR1004274B (el) 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
AU2003262025A1 (en) * 2002-09-12 2004-04-30 Nihon Medi-Physics Co., Ltd. Preparation for controlling binging of drug to plasma protein
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
US20050079546A1 (en) * 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US8391959B2 (en) * 2004-09-29 2013-03-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Composition for improving efficiency of drug delivery
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
PT2079456E (pt) 2007-04-04 2013-03-13 Sigmoid Pharma Ltd Composições farmacêuticas de ciclosporina
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2009116557A1 (ja) * 2008-03-21 2009-09-24 富士フイルム株式会社 薬剤含有組成物
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
BRPI1012196B1 (pt) 2009-05-18 2021-11-30 Sublimity Therapeutics Limited Composição compreendendo gotas de óleo
GB2485327A (en) 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038068A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes
CN102802617B (zh) * 2009-12-18 2016-05-11 埃克索多斯生命科学有限合伙公司 用于稳定的液体药物制剂的方法和组合物
WO2011097149A2 (en) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Taxane-and taxoid-protein compositions
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2942867C (en) 2014-03-18 2022-08-30 Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
CN107106644B (zh) 2014-11-07 2022-04-15 卓越治疗有限公司 包含环孢菌素的组合物
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
WO2016182929A1 (en) 2015-05-08 2016-11-17 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
WO2016187147A1 (en) * 2015-05-15 2016-11-24 Fl Therapeutics Llc Docetaxel and human serum albumin complexes
CN107920991A (zh) * 2015-06-18 2018-04-17 马丁尼斯生物制药纳米技术公司 治疗炎性疾病或病状的组合物和方法
US20170128480A1 (en) * 2015-11-09 2017-05-11 Max A. Cayo Cardiac Glycosides for the Treatment of Hypercholesterolemia
CN109789154B (zh) * 2016-08-03 2021-05-14 珠海贝海生物技术有限公司 福沙吡坦和阿瑞吡坦的制剂
CN115487312A (zh) 2016-10-27 2022-12-20 珠海贝海生物技术有限公司 多西他赛和人血清白蛋白的中性pH组合物
JP7134995B2 (ja) 2017-03-20 2022-09-12 スペクトラル プラットフォームス インコーポレイテッド 微生物を検出し特徴づけるための分光法
BR112020000196A2 (pt) 2017-07-07 2020-07-07 Epicentrx, Inc. composições para administração parenteral de agentes terapêuticos
PL3761960T3 (pl) 2018-03-09 2024-04-15 Kiora Pharmaceuticals Gmbh Preparat okulistyczny
EP3811982A1 (de) * 2019-10-25 2021-04-28 Université de Strasbourg Biomaterial auf proteinbasis mit viskoelastischem verhalten, verfahren zur herstellung davon und verwendungen davon
CN111529506B (zh) * 2020-05-18 2021-09-03 同济大学 一种两性霉素b白蛋白纳米制剂及其制备方法和应用
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CN114544926A (zh) * 2021-12-02 2022-05-27 浙江鑫科医疗科技有限公司 一种血清蛋白稳定剂
CN115236216B (zh) * 2022-06-07 2024-03-01 合肥和合医疗科技有限公司 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒，其制备方法和检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833013A (de) * 1971-08-30 1973-05-07
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5356927A (en) * 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
TR199600775A2 (tr) 1996-09-27 1997-09-21 Tureks Turunc Madencilik Ic Ve Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem.
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
NO325294B1 (no) 2008-03-17
EP0981375A1 (de) 2000-03-01
BG104245A (en) 2000-11-30
NO20001371L (no) 2000-05-18
LV12493B (en) 2001-01-20
CN1189216C (zh) 2005-02-16
CN1270529A (zh) 2000-10-18
PL193067B1 (pl) 2007-01-31
PT981375E (pt) 2003-04-30
EP0981375B1 (de) 2003-01-08
ATE230611T1 (de) 2003-01-15
DE69810612T2 (de) 2003-10-02
US20100076008A1 (en) 2010-03-25
TR200001545T2 (tr) 2000-10-23
BG64749B1 (bg) 2006-02-28
US7501455B2 (en) 2009-03-10
ZA988585B (en) 2000-03-13
ES2187062T3 (es) 2003-05-16
BR9812469A (pt) 2002-02-05
RO118695B1 (ro) 2003-09-30
KR20010052072A (ko) 2001-06-25
US20050064028A1 (en) 2005-03-24
AU9362398A (en) 1999-04-05
CA2269923C (en) 2003-07-22
LT4736B (lt) 2000-12-27
EA200000331A1 (ru) 2000-10-30
TWI222365B (en) 2004-10-21
IL135055A (en) 2004-09-27
CA2269923A1 (en) 1999-03-25
US8946167B2 (en) 2015-02-03
SI20189A (sl) 2000-10-31
HUP9701554D0 (en) 1997-11-28
LV12493A (en) 2000-06-20
EA004700B1 (ru) 2004-06-24
RS50102B (sr) 2009-01-22
WO1999013914A1 (en) 1999-03-25
LT2000018A (en) 2000-08-25
PL339369A1 (en) 2000-12-18
JP2001508806A (ja) 2001-07-03
NZ503302A (en) 2001-08-31
IL135055A0 (en) 2001-05-20
SI20189B (sl) 2007-10-31
US6743826B1 (en) 2004-06-01
DK0981375T3 (da) 2003-05-05
NO20001371D0 (no) 2000-03-16
SK284683B6 (sk) 2005-09-08
HRP980499A2 (en) 1999-12-31
US7119124B2 (en) 2006-10-10
US20040014655A1 (en) 2004-01-22
KR100587962B1 (ko) 2006-06-13
CZ301326B6 (cs) 2010-01-20
AR017120A1 (es) 2001-08-22
CZ2000952A3 (cs) 2000-09-13
US20070232536A1 (en) 2007-10-04
SK3292000A3 (en) 2000-08-14
AU734695B2 (en) 2001-06-21
YU16600A (sh) 2003-08-29

Similar Documents

Publication Publication Date Title
DE69810612T2 (de) Pharmazeutische Zusammensetzungen mit Plasmaproteinen
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
ID24654A (id) Formulasi farmasi omeprazola
BR9611367A (pt) Formulação farmacêutic liofilizada estável
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
DE69807420D1 (de) Pharmazeutische aerosolzusammensetzung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE59915033D1 (de) Pharmazeutische Zubereitung
ID27150A (id) Sediaan levotiroksin bahan farmasi
EE04001B1 (et) Peptiidne farmatseutiline kompositsioon
DE69614407D1 (de) Pharmazeutische zusammensetzungen
DE69830154D1 (de) Pharmazeutische zusammensetzungen
ATE208364T1 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
DE69926012D1 (de) Arzneizubereitungen
ID25857A (id) Komposisi farmasi
DE69906934D1 (de) Arzneizubereitungen
DE19681529D2 (de) Pharmazeutische Darreichungsform
ID23531A (id) Komposisi farmasi
FI974610A0 (fi) Farmaceutiskt preparat i gelform
ATA77096A (de) Pharmazeutische präparation
BR1100755A (pt) composição farmacêutica
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
BR1100391A (pt) Composto e composição farmacêutica

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TEVA PHARMACEUTICALS WORKS PLC., DEBRECEN, HU